Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Psychotropic Use and Psychotropic Polypharmacy in a Finnish National Cohort of Persons With Intellectual Disabilities.

Journal of intellectual disability research : JIDR·2026
Same author

Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study.

Pharmacoepidemiology and drug safety·2026
Same author

Validation of Parkinson's Disease Diagnoses in a National Register: Accuracy, Limitations, and Utility.

Clinical epidemiology·2026
Same author

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Mortality of People With Alzheimer's Disease and Psychiatric Morbidity: A Nationwide Finnish Cohort Study.

International journal of geriatric psychiatry·2026
Same author

Psychotropic medication use among community dwellers with and without Parkinson's disease - A nationwide cohort study.

British journal of clinical pharmacology·2026

Related Experiment Video

Updated: May 23, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Association Between Furosemide and Risk of Parkinson's Disease in a Nested Case-Control Study.

Barkat Babar1,2, Anne Paakinaho1,2, Emeline Courtois3

  • 1School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Basic & Clinical Pharmacology & Toxicology
|May 21, 2026
PubMed
Summary

This study investigated if furosemide, a diuretic, lowers Parkinson's disease (PD) risk. While not robustly confirmed, higher furosemide exposure showed a borderline association with reduced PD risk in Finnish patients.

Keywords:
Parkinson's diseasefurosemideheart failurerenal failure

Related Experiment Videos

Last Updated: May 23, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Area of Science:

  • Neurology
  • Pharmacology
  • Epidemiology

Background:

  • Previous French research suggested sulfonamide diuretics, like furosemide, may reduce Parkinson's disease (PD) risk.
  • The FINPARK study aimed to validate this association in a Finnish population.

Purpose of the Study:

  • To confirm the association between furosemide use and Parkinson's disease risk.
  • To investigate this link specifically in patients with heart or renal failure.

Main Methods:

  • A nationwide nested case-control study (FINPARK) included 19,568 PD cases and 130,156 controls.
  • An indication-restricted analysis focused on 1,222 PD cases with heart/renal failure and 4,766 controls.
  • Furosemide exposure was assessed using prescription data with various lag times (3, 5, 8 years).

Main Results:

  • Furosemide use was not significantly associated with PD risk (OR 1.00, 95% CI 0.87-1.15 with a 3-year lag).
  • A borderline statistically significant association (OR 0.80, 95% CI 0.64-1.00) was observed between higher cumulative furosemide exposure and lower PD risk.
  • No robust evidence for a link was found, but a suggestive reduced risk was noted in the highest exposure category.

Conclusions:

  • The Finnish nationwide study did not find robust evidence supporting furosemide use in reducing Parkinson's disease risk.
  • Suggestive evidence indicated a potential risk reduction in individuals with the highest cumulative furosemide exposure.